{"id":"icotinib-with-concurrent-radiotherapy","safety":{"commonSideEffects":[{"rate":"34%","effect":"Diarrhea"},{"rate":"28%","effect":"Nausea"},{"rate":"21%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL2087361","moleculeType":"Small molecule","molecularWeight":"391.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Icotinib is a small molecule inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase, thereby inhibiting the proliferation of cancer cells.","oneSentence":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:34:55.425Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT03754530","phase":"PHASE2","title":"Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2018-12-01","conditions":"Non-Small Cell Lung Cancer, Brain Metastases","enrollment":162},{"nctId":"NCT02714010","phase":"PHASE3","title":"EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Non-Small Cell Lung Cancer","enrollment":601},{"nctId":"NCT03258671","phase":"NA","title":"IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer","status":"UNKNOWN","sponsor":"LuBing","startDate":"2017-10-01","conditions":"Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung","enrollment":160},{"nctId":"NCT01724801","phase":"PHASE3","title":"Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer","status":"COMPLETED","sponsor":"Guangdong Association of Clinical Trials","startDate":"2012-10-14","conditions":"Brain Metastasis, Non Small Cell Lung Cancer","enrollment":176},{"nctId":"NCT02883543","phase":"PHASE3","title":"First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation","status":"UNKNOWN","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2016-06","conditions":"Non-small Cell Lung Cancer","enrollment":330},{"nctId":"NCT02788058","phase":"PHASE2","title":"A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2016-05","conditions":"Lung Adenocarcinoma, EGFR Positive Non-small Cell Lung Cancer","enrollment":76},{"nctId":"NCT02738983","phase":"PHASE2","title":"RT Plus EGFR-TKI for Wild-type NSCLC","status":"UNKNOWN","sponsor":"Hangzhou Cancer Hospital","startDate":"2012-01","conditions":"Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)","enrollment":22},{"nctId":"NCT02375581","phase":"PHASE2","title":"Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2015-01","conditions":"Esophageal Cancer","enrollment":130},{"nctId":"NCT01926171","phase":"PHASE4","title":"Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2013-06","conditions":"Non-small-cell Lung Cancer","enrollment":80},{"nctId":"NCT02407366","phase":"PHASE2","title":"Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"People's Hospital of Guangxi Zhuang Autonomous Region","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer","enrollment":80},{"nctId":"NCT02215356","phase":"PHASE2","title":"Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-08","conditions":"Non-small Cell Lung Cancer","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Icotinib","Comana","BPI-2009"],"phase":"phase_2","status":"active","brandName":"Icotinib with concurrent radiotherapy","genericName":"Icotinib with concurrent radiotherapy","companyName":"Betta Pharmaceuticals Co., Ltd.","companyId":"betta-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}